KK3A Panoramica delle azioni Cytokinetics, Incorporated, un'azienda biofarmaceutica in fase avanzata, si concentra sulla scoperta, lo sviluppo e la commercializzazione di attivatori e inibitori muscolari come potenziali trattamenti per malattie debilitanti. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Cytokinetics, Incorporated Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Cytokinetics Prezzi storici delle azioni Prezzo attuale dell'azione US$46.40 Massimo di 52 settimane US$75.50 Minimo di 52 settimane US$43.20 Beta 0.82 Variazione di 1 mese 3.57% Variazione a 3 mesi -0.85% Variazione di 1 anno -37.30% Variazione a 3 anni 60.00% Variazione a 5 anni 265.35% Variazione dall'IPO 90.48%
Notizie e aggiornamenti recenti
Cytokinetics Announces Start of AMBER-HFpEF, A Phase 2 Clinical Trial of CK-586 in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction Jan 21
Cytokinetics, Incorporated Announces Start of COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction Dec 03
Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Dec 02
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 18
Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024 Nov 17
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 16 Vedi altri aggiornamenti
Cytokinetics Announces Start of AMBER-HFpEF, A Phase 2 Clinical Trial of CK-586 in Patients with Symptomatic Heart Failure with Preserved Ejection Fraction Jan 21
Cytokinetics, Incorporated Announces Start of COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction Dec 03
Cytokinetics, Incorporated Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy Dec 02
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 18
Cytokinetics, Incorporated Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy At the American Heart Association Scientific Sessions 2024 Nov 17
Cytokinetics, Incorporated Presents Additional Data from GALACTIC-HF At the American Heart Association Scientific Sessions 2024 Nov 16
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4015089 Nov 12
New major risk - Negative shareholders equity Nov 08
Third quarter 2024 earnings released: US$1.36 loss per share (vs US$1.35 loss in 3Q 2023) Nov 08
Cytokinetics, Incorporated to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Cytokinetics Presents Additional Data from EQUOIA-HCM At the HCMS Scientific Sessions Sep 28 Cytokinetics, Incorporated Presents Additional Data from SEQUOIA-HCM at the European Society of Cardiology Congress 2024
Second quarter 2024 earnings released: US$1.31 loss per share (vs US$1.34 loss in 2Q 2023) Aug 09
New minor risk - Share price stability Aug 08
Cytokinetics, Incorporated to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
CEO, President & Director recently sold €580k worth of stock Jul 02
CEO, President & Director recently sold €1.1m worth of stock Jun 18
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants Jun 18
New minor risk - Share price stability Jun 06
VP & Chief Accounting Officer recently sold €584k worth of stock Jun 06
New minor risk - Insider selling Jun 05 Cytokinetics, Incorporated announced that it has received $49.999992 million in funding from Royalty Pharma Development Funding, LLC May 30
Cytokinetics, Incorporated has completed a Follow-on Equity Offering in the amount of $500.000022 million.
Cytokinetics, Incorporated Announces Resignation of Sandford D. Smith as Board of Directors May 18
First quarter 2024 earnings released: US$1.33 loss per share (vs US$1.38 loss in 1Q 2023) May 09 Cytokinetics, Incorporated Announces CEDAR-HCM Is Open to Enrollment Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024
Cytokinetics, Incorporated to Report Q1, 2024 Results on May 08, 2024 Apr 26
Cytokinetics, Incorporated, Annual General Meeting, May 15, 2024 Apr 09
Cytokinetics Presents Additional 48-Week Data from Forest-Hcm, the Open Label Extension Clinical Study of Aficamten, At the American College of Cardiology 73rd Annual Scientific Session Apr 05
Cytokinetics, Incorporated Provides Revenue Guidance for 2024 Feb 29
Full year 2023 earnings released: US$5.45 loss per share (vs US$4.33 loss in FY 2022) Feb 28
New major risk - Revenue and earnings growth Feb 28
Cytokinetics, Incorporated to Report Q4, 2023 Results on Feb 27, 2024 Feb 14 Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw as Chief Financial Officer, Effective February 23, 2024 Feb 04
Cytokinetics, Incorporated Announces Resignation of Ching W. Jaw, Senior Vice President, Effective February 23, 2024 Feb 03
Novartis Pursuit of Cytokinetics Reportedly Cools Jan 12 Novartis Reportedly in Advanced Talks to Buy Cytokinetics Jan 09
Cytokinetics, Incorporated Announces Positive Results from Sequoia-Hcm, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy Dec 28
Now 20% undervalued Dec 20
Cytokinetics Presents Results from COURAGE-ALS At the 34th International Symposium on ALS/MND Dec 08
Insufficient new directors Dec 01
New minor risk - Shareholder dilution Nov 06
Third quarter 2023 earnings released: US$1.35 loss per share (vs US$1.52 loss in 3Q 2022) Nov 03
Cytokinetics, Incorporated to Report Q3, 2023 Results on Nov 02, 2023 Oct 24
Cytokinetics, Incorporated Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day Oct 20
New minor risk - Share price stability Oct 10
Cytokinetics, Incorporated Presents Baseline Characteristics from SEQUOIA-HCM at the HCM Society Oct 08
Second quarter 2023 earnings released: US$1.34 loss per share (vs US$0.23 loss in 2Q 2022) Aug 04
Cytokinetics, Incorporated to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Cytokinetics, Incorporated Presents New Data in Patients with Non-Obstructive Hcm from Cohort 4 of Redwood-Hcm in Late-Breaking Clinical Trial Session At the European Society of Cardiology Heart Failure 2023 Congress May 24
Cytokinetics, Incorporated Announces Initiation of Phase 1 Clinical Study of CK-4021586 May 12
First quarter 2023 earnings released: US$1.38 loss per share (vs US$1.05 loss in 1Q 2022) May 05
Now 22% undervalued after recent price drop Apr 13
Now 20% undervalued after recent price drop Mar 23
Full year 2022 earnings released: US$4.33 loss per share (vs US$2.80 loss in FY 2021) Mar 03
Cytokinetics, Incorporated to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Cytokinetics, Incorporated Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil Dec 15
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-3828136 Dec 08
VP & Chief Accounting Officer recently sold €83k worth of stock Nov 17
Cytokinetics, Incorporated Presents New Data at the American Heart Association Scientific Sessions 2022 Nov 08
Third quarter 2022 earnings released: US$1.52 loss per share (vs US$0.95 loss in 3Q 2021) Nov 05
Cytokinetics, Incorporated to Report Q3, 2022 Results on Nov 03, 2022 Oct 21
Cytokinetics, Incorporated Announces Continuation of COURAGE-ALS Following First Interim Analysis Oct 11
Cytokinetics, Incorporated Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions Oct 01
Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.86 loss in 2Q 2021) Aug 06
Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics' Completed ALS Clinical Trials Aug 05
Cytokinetics, Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 22
Cytokinetics, Incorporated Provides Update on New Drug Application Jun 18
Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS Jun 17
Cytokinetics, Incorporated Announces Additional Data from Redwood-HCM Presented At the American Society of Echocardiography 33Rd Annual Scientific Sessions Jun 14
First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.66 loss in 1Q 2021) May 06
Cytokinetics, Incorporated to Report Q1, 2022 Results on May 04, 2022 Apr 21
Cytokinetics, Incorporated Announces Retirement of Mark A. Schlossberg as Senior Vice President, Legal, General Counsel and Secretary, Effective May 13, 2022 Apr 16 Cytokinetics, Incorporated Announces Changes to Board of Directors Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session
Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment Mar 04
Cytokinetics, Incorporated Announces Cohort 4 of REDWOOD-HCM is Open to Enrollment Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 26
Cytokinetics, Incorporated Provides Earnings Guidance for the Year 2022 Feb 25
Cytokinetics, Incorporated Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy Feb 24
Cytokinetics, Incorporated Announces Resignation of Robert M. Califf as Member of the Board of Directors Feb 17
Cytokinetics, Incorporated Announces Topline Results From METEORIC-HF Feb 16 Rendimenti per gli azionisti KK3A DE Biotechs DE Mercato 7D 3.1% 1.0% 2.0% 1Y -37.3% -4.8% 15.2%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: KK3A ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -4.8 % nell'ultimo anno.
Rendimento vs Mercato: KK3A ha avuto una performance inferiore al mercato German che ha registrato un rendimento 15.2 % nell'ultimo anno.
Volatilità dei prezzi Is KK3A's price volatile compared to industry and market? KK3A volatility KK3A Average Weekly Movement 5.8% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Prezzo delle azioni stabile: KK3A non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato German.
Volatilità nel tempo: La volatilità settimanale ( 6% ) di KK3A è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Cytokinetics, Incorporated, un'azienda biofarmaceutica in fase avanzata, si concentra sulla scoperta, lo sviluppo e la commercializzazione di attivatori e inibitori muscolari come potenziali trattamenti per malattie debilitanti. L'azienda sviluppa candidati farmaci a base di piccole molecole, principalmente studiati per influenzare la funzione e la contrattilità muscolare. I candidati farmaci dell'azienda includono omecamtiv mecarbil, un nuovo attivatore della miosina cardiaca che è in fase III di sperimentazione clinica in pazienti con insufficienza cardiaca.
Mostra di più Cytokinetics, Incorporated Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Cytokinetics con la sua capitalizzazione di mercato? KK3A statistiche fondamentali Capitalizzazione di mercato €5.52b Guadagni(TTM ) -€553.92m Ricavi(TTM ) €3.09m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) KK3A Conto economico (TTM ) Ricavi US$3.22m Costo del fatturato US$330.76m Profitto lordo -US$327.54m Altre spese US$248.87m Guadagni -US$576.40m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) -4.88 Margine lordo -10,175.09% Margine di profitto netto -17,906.24% Rapporto debito/patrimonio netto -5,568.4%
Come si è comportato KK3A nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/30 15:02 Prezzo dell'azione a fine giornata 2025/01/30 00:00 Guadagni 2024/09/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Cytokinetics, Incorporated è coperta da 37 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Carter Gould Barclays Jason Zemansky BofA Global Research Mayank Mamtani B. Riley Securities, Inc.
Mostra 34 altri analisti 
